- List articles in this issue
Teledermatological Monitoring of Psoriasis Patients on Biologic Therapy
Patients with psoriasis who are being treated with biologics require intensive monitoring. However, the monitoring tool teledermatology is not commonly used. We investigated the applicability of a mobile phone based teledermatological system for monitoring psoriasis patients on biologic therapy. Nineteen patients were given mobile phones with built-in cameras, in order to transmit health status data and images (mobile visits) weekly for a 6-month period. Face-to-face visits were carried out at weeks 0, 4, 12 and 24. Image quality, the Psoriasis Area and Severity Index (PASI), the handling of adverse events, and patients’ feedback questionnaires were evaluated. Ninety-five percent of the images were of sufficient quality to enable accurate assessment of the PASI. The distance between the interpolated face-to-face PASIs and the corresponding mobile visit PASIs was 0.46 ± 2.15 (median ± interquartile range). All 155 adverse events were handled correctly by the system. This teledermatological system represents a reliable tool for management of psoriasis patients who are on systemic treatment.
Silvia Koller, Rainer Hofmann-Wellenhof, Dieter Hayn, Wolfgang Weger, Peter Kastner, Günter Schreier, Wolfgang Salmhofer
Finzi AF, Benelli C. A clinical survey of psoriasis in Italy: 1st AISP report. Interdisciplinary Association for the Study of Psoriasis. J Eur Acad Dermatol Venereol 1998; 10: 125–129.
Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141: 1537–1541.
Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology 2006; 212: 327-337.
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826–850.
Meier M, Sheth PB. Clinical spectrum and severity of psoriasis. Curr Probl Dermatol 2009; 38: 1–20.
Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010; 160: 810–820.
Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1–70. Erratum in: J Eur Acad Dermatol Venereol 2010; 24: 117–118.
Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401–407.
Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: 408–414.
Carroll CL, Feldman SR, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004; 151: 895–897.
Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581–583.
Gokdemir G, Ari S, Köslü A. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol 2008; 22: 330–335.
Eminović N, de Keizer NF, Bindels PJ, Hasman A. Maturity of teledermatology evaluation research: a systematic literature review. Br J Dermatol 2007; 156: 412–419.
Hsiao JL, Oh DH. The impact of store-and-forward teledermatology on skin cancer diagnosis and treatment. J Am Acad Dermatol 2008; 59: 260–267.
May C, Giles L, Gupta G. Prospective observational comparative study assessing the role of store and forward teledermatology triage in skin cancer. Clin Exp Dermatol 2008; 33: 736–739.
Moreno-Ramirez D, Ferrandiz L, Ruiz-de-Casas A, Nieto-Garcia A, Moreno-Alvarez P, Galdeano R, et al. Economic evaluation of a store-and-forward teledermatology system for skin cancer patients. J Telemed Telecare 2009; 15: 40–45.
Massone C, Brunasso AM, Campbell TM, Soyer HP. Mobile teledermoscopy – melanoma diagnosis by one click? Semin Cutan Med Surg 2009; 28: 203–205.
Massone C, Hofmann-Wellenhof R, Ahlgrimm-Siess V, Gabler G, Ebner C, Soyer HP. Melanoma screening with cellular phones. PLoS One 2007; 30: e483.
Piccolo D, Smolle J, Wolf IH, Peris K, Hofmann-Wellenhof R, Dell’Eva G, et al. Face-to-face diagnosis vs telediagnosis of pigmented skin tumors: a teledermoscopic study. Arch Dermatol 1999; 135: 1467–1471.
Binder B, Hofmann-Wellenhof R, Salmhofer W, Okcu A, Kerl H, Soyer HP. Teledermatological monitoring of leg ulcers in cooperation with home care nurses. Arch Dermatol 2007; 143: 1511–1514.
Salmhofer W, Hofmann-Wellenhof R, Gabler G, Rieger-Engelbogen K, Gunegger D, Binder B, et al. Wound teleconsultation in patients with chronic leg ulcers. Dermatology 2005; 210: 211–217.
Frühauf J, Schwantzer G, Ambros-Rudolph CM, Weger W, Ahlgrimm-Siess V, Salmhofer W, et al. Pilot study using teledermatology to manage high-need patients with psoriasis. Arch Dermatol 2010; 146: 200–201.
Weisenseel P, Kuznetsov AV, Prinz JC. Implementation of the S3-guidelines for systemic and UV therapy of moderate to severe psoriasis vulgaris by an algorithm. J Dsch Dermatol Ges 2007; 5: 683–688.
Fleischer AB JR, Feldman SR, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol 1999; 26: 210–215.
Hayn D, Koller S, Hofmann-Wellenhof R, Salmhofer W, Kastner P, Schreier G. Mobile phone-based teledermatologic compliance management – preliminary results of the TELECOMP study. Stud Health Technol Inform 2009; 150: 468–472.
EMEA. European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab). Available from: URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/20855709en.pdf [accessed Feb 9, 2009].
There are no related articles.
Share with your friends
There is no supplementary for this article.
Volume 91, Issue 6
View at PubMed